Luqa Pharmaceuticals and Stratpharma enter into an exclusive agreement
- Details
- Category: Business
Luqa Pharmaceuticals announced today that it has entered into an exclusive agreement with Stratpharma AG of Switzerland to promote, sell, and distribute Strataderm®, in the People's Republic of China.
Affinium Pharmaceuticals announces completion of recruitment for Phase 2 clinical trial of AFN-1252
- Details
- Category: Clinical Trials
Affinium Pharmaceuticals announced that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").
Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has announced an agreement with Servier and its partner XOMA Corporation (Nasdaq: XOMA) to transfer XOMA's technology and process for the commercial manufacture of gevokizumab, XOMA's novel interleukin 1-beta (IL-1β) allosteric modulating antibody.
Bristol-Myers Squibb Foundation awards $1.6 million in grants
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation announced $1.6 million in grants to four health care institutions in India that will help improve diabetes education, prevention and care and increase health care worker capacity in rural and tribal areas and among the urban poor.
Novartis and University of Pennsylvania form broad-based R&D alliance
- Details
- Category: Novartis
Novartis and the University of Pennsylvania (Penn) announced today an exclusive global collaboration to research, develop and commercialize targeted chimeric antigen receptor (CAR) immunotherapies for the treatment of cancers.
Sanofi second-quarter and first-half sales 2012
- Details
- Category: Sanofi
In the second quarter of 2012, Sanofi generated net sales of €8,870 million, up 6.2% on a reported basis. Exchange rate movements had a positive effect of 5.8 percentage points reflecting the appreciation of the U.S. dollar and, to a lesser extent, the appreciation of the Japanese Yen and Chinese Yuan against the Euro.
UCB half year results 2012: on track for growth
- Details
- Category: UCB
UCB has announced its consolidated half year 2012 financial results. The first half year was marked by continuous execution and growth of core medicines Cimzia® (certolizumab pegol), Vimpat® (lacosamide) and Neupro® (rotigotine) with combined net sales total exceeding EUR 413 million (+45%).
More Pharma News ...
- Pfizer reports second-quarter 2012 results
- Bayer reports strong business performance in the second quarter of 2012
- Roche reports second positive study of RoACTEMRA
- Amgen's second quarter 2012 revenues increased 13 percent to $4.5 billion
- AstraZeneca PLC Second quarter and half year results 2012
- Lilly reports second-quarter 2012 results
- Pfizer reports top-line results of study of Lyrica's effect on male reproduction